ES2566646T3 - Vacunas en nanoemulsión - Google Patents

Vacunas en nanoemulsión Download PDF

Info

Publication number
ES2566646T3
ES2566646T3 ES10790134.0T ES10790134T ES2566646T3 ES 2566646 T3 ES2566646 T3 ES 2566646T3 ES 10790134 T ES10790134 T ES 10790134T ES 2566646 T3 ES2566646 T3 ES 2566646T3
Authority
ES
Spain
Prior art keywords
vol
approximately
oil
dih2o
chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10790134.0T
Other languages
English (en)
Spanish (es)
Inventor
Nicholas W. Lukacs
Dennis M. Lindell
James R. Baker, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Application granted granted Critical
Publication of ES2566646T3 publication Critical patent/ES2566646T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES10790134.0T 2009-06-16 2010-06-16 Vacunas en nanoemulsión Active ES2566646T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US187529P 2000-03-07
US18752909P 2009-06-16 2009-06-16
PCT/US2010/038854 WO2010148111A1 (en) 2009-06-16 2010-06-16 Nanoemulsion vaccines

Publications (1)

Publication Number Publication Date
ES2566646T3 true ES2566646T3 (es) 2016-04-14

Family

ID=43306638

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10790134.0T Active ES2566646T3 (es) 2009-06-16 2010-06-16 Vacunas en nanoemulsión

Country Status (8)

Country Link
US (1) US20100316673A1 (cg-RX-API-DMAC7.html)
EP (2) EP2442827B1 (cg-RX-API-DMAC7.html)
JP (2) JP6110140B2 (cg-RX-API-DMAC7.html)
CN (1) CN102596243B (cg-RX-API-DMAC7.html)
BR (1) BRPI1014031A2 (cg-RX-API-DMAC7.html)
CA (1) CA2765511C (cg-RX-API-DMAC7.html)
ES (1) ES2566646T3 (cg-RX-API-DMAC7.html)
WO (1) WO2010148111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2729169A1 (en) * 2011-07-06 2014-05-14 Nanobio Corporation Human respiratory syncytial virus vaccine
EP3488863A1 (en) * 2011-09-09 2019-05-29 Nanobio Corporation Nanoemulsion respiratory syncytial virus (rsv) subunit vaccine
EP4112076A1 (en) * 2014-10-10 2023-01-04 The Regents of The University of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
EP3651794A1 (en) * 2017-07-13 2020-05-20 Nanobio Corporation Chlamydia nanoemulsion vaccine
AU2018357917B2 (en) 2017-10-30 2024-08-01 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2022149609A1 (ja) * 2021-01-07 2022-07-14 国立大学法人東京工業大学 Ｍｈｃ分子に適合する病原微生物由来のペプチドが担持された複合蛋白質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン、並びに、免疫後の生理活性物質の分泌に関する情報の取得方法
CN117693360A (zh) * 2021-04-08 2024-03-12 科达金尼克斯有限公司 引发针对呼吸道合胞病毒的免疫应答的方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
EP0073856A1 (en) * 1981-08-28 1983-03-16 Gist-Brocades N.V. Infectious-bronchitis vaccines for poultry, combined infectious-bronchitis vaccines, process for preparing such vaccines, process for preventing infectious bronchitis and infectious-bronchitis virus strain
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
NL8301996A (nl) * 1983-06-06 1985-01-02 Duphar Int Res Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins.
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4895452A (en) * 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5103497A (en) 1989-11-14 1992-04-07 Hicks John W Flying spot endoscope
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5389369A (en) 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1247472B (it) 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
DE69228247T2 (de) 1991-08-10 1999-07-08 Medical Research Council, London Behandlung von Zellpopulationen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6350784B1 (en) * 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US5951988A (en) * 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US7223410B1 (en) * 1994-08-05 2007-05-29 Sanofi Pasteur Limited Inactivated respiratory syncytial viral vaccines
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
CN1055093C (zh) 1993-11-17 2000-08-02 实验室奥姆公司 葡糖胺二糖类、其制备方法和用途、以及含有这些二糖的药物组合物
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5547677A (en) 1994-05-20 1996-08-20 Novavax, Inc. Antimicrobial oil-in-water emulsions
EP0765151B1 (en) * 1994-05-20 2002-01-09 Novavax, Inc. Antibacterial oil-in-water emulsions
US5549901A (en) * 1994-05-20 1996-08-27 Novavax, Inc. Antimicrobial oil-in-water emulsions
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5662957A (en) * 1996-05-03 1997-09-02 Novavax, Inc. Oil containing lipid vesicles with marine applications
US5700679A (en) 1996-06-07 1997-12-23 Novavax, Inc. Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
DE69719761T2 (de) 1996-06-18 2003-12-18 Alza Corp., Palo Alto Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
AU722574B2 (en) 1996-12-20 2000-08-10 Alza Corporation Device and method for enhancing transdermal agent flux
US6627198B2 (en) * 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
US6645495B1 (en) 1997-08-29 2003-11-11 Antigenics, Inc. Compositions of saponin adjuvants and excipients
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
CA2312900A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6814968B1 (en) * 1998-06-04 2004-11-09 Vanderbilt University Inhibition of viral infection and spread with viral and RhoA-derived peptides
US7357936B1 (en) * 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
ATE297190T1 (de) * 1999-02-26 2005-06-15 Chiron Corp Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
ES2350306T3 (es) * 1999-02-26 2011-01-20 Novartis Vaccines And Diagnostics, Inc. Uso de bioadhesivos y adyuvantes para la administración de antígenos por vía mucosa.
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
US6635676B2 (en) * 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US7767216B2 (en) * 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
AU783601B2 (en) * 1999-12-30 2005-11-10 Kimberly-Clark Worldwide, Inc. Antimicrobial absorbent article, and methods of making and using the same
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
US20020155084A1 (en) * 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US6565873B1 (en) * 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
EP2545937A1 (en) * 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
AU2002347062B2 (en) 2001-10-06 2008-06-26 Merial Ltd CpG formulations and related methods
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
CA2533581C (en) * 2003-07-24 2012-05-08 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
CA2572389A1 (en) * 2004-06-30 2006-06-29 Id Biomedical Corporation Of Quebec Vaccine compositions for treating coronavirus infection
US8691781B2 (en) * 2004-11-05 2014-04-08 Sirnaomics, Inc. Compositions for treating respiratory viral infections and their use
EP1861067A2 (en) * 2005-03-09 2007-12-05 Combe Incorporated Stable mixed emulsions comprising semisolid dispersions of at least two discrete and distinctly different particle size ranges
EP1951200A2 (en) * 2005-08-09 2008-08-06 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US20070292688A1 (en) * 2005-08-18 2007-12-20 Eastman Kodak Company Silylamine modified nanoparticulate carriers
US20080039295A1 (en) * 2006-08-14 2008-02-14 Zeev Steinmetz Method and device to enable and assist the elderly and females to exercise their abdominal and lower back muscles
US8747872B2 (en) * 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
CA2826508C (en) * 2008-05-23 2016-07-19 The Regents Of The University Of Michigan Nanoemulsion vaccines
AU2009293595A1 (en) * 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants

Also Published As

Publication number Publication date
CA2765511C (en) 2015-05-12
EP2442827A4 (en) 2013-04-17
WO2010148111A1 (en) 2010-12-23
JP6122083B2 (ja) 2017-04-26
JP2012530146A (ja) 2012-11-29
JP6110140B2 (ja) 2017-04-05
EP2442827B1 (en) 2016-01-06
US20100316673A1 (en) 2010-12-16
CN102596243B (zh) 2015-10-21
EP3020412B1 (en) 2017-10-11
EP3020412A1 (en) 2016-05-18
BRPI1014031A2 (pt) 2018-02-20
CA2765511A1 (en) 2010-12-23
HK1173661A1 (zh) 2013-05-24
CN102596243A (zh) 2012-07-18
JP2016026202A (ja) 2016-02-12
EP2442827A1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
US8877208B2 (en) Multivalent nanoemulsion vaccines
US12403192B2 (en) Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
US8668911B2 (en) Streptococcus vaccine compositions and methods of using the same
JP6122083B2 (ja) ナノエマルションワクチン
US20140093537A1 (en) Immunogenic compositions comprising nanoemulsion and methods of administering the same
US20130273113A1 (en) Immunogenic apoptosis inducing compositions and methods of use thereof
AU2014201214B2 (en) Nanoemulsion vaccines
US20120258137A1 (en) Immunogenic compositions comprising nanoemulsion and hepatitis b virus immunogen and methods of using the same
HK1173661B (en) Nanoemulsion vaccines